Cargando…

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

BACKGROUND: Achieving good adherence to self-injected treatments for multiple sclerosis can be difficult. Injection devices may help to overcome some of the injection-related barriers to adherence that can be experienced by patients. We sought to assess short-term adherence to, and tolerability of,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lugaresi, Alessandra, Florio, Ciro, Brescia-Morra, Vincenzo, Cottone, Salvatore, Bellantonio, Paolo, Clerico, Marinella, Centonze, Diego, Uccelli, Antonio, di Ioia, Maria, De Luca, Giovanna, Marcellusi, Andrea, Paolillo, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368780/ https://www.ncbi.nlm.nih.gov/pubmed/22390218 http://dx.doi.org/10.1186/1471-2377-12-7

Ejemplares similares

Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study
por: Patti, Francesco, et al.
Publicado: (2013)

Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration
por: La Rocca, Claudia, et al.
Publicado: (2017)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Digital Health Integration Assessment and Maturity of the United States Biopharmaceutical Industry: Forces Driving the Next Generation of Connected Autoinjectable Devices
por: Rafiei, Ramin, et al.
Publicado: (2021)

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
por: Laroni, Alice, et al.
Publicado: (2014)

Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
por: Maglione, Alessandro, et al.
Publicado: (2022)

MULTICENTRE DOUBLE-BLIND STUDY OF EFFECT OF INTRATHECALLY ADMINISTERED NATURAL HUMAN FIBROBLAST INTERFERON ON EXACERBATIONS OF MULTIPLE SCLEROSIS()
por: Jacobs, Lawrence, et al.
Publicado: (1986)

Efficacy and safety of autoinjected exenatide once‐weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION‐NEO‐2 randomized clinical study
por: Gadde, Kishore M., et al.
Publicado: (2017)

Patient Ability to Use Old versus New/Modified Model Adrenaline Autoinjection Emergency Medical Devices for Anaphylaxis in Prehospital Setting: A Systematic Review and Meta-Analysis
por: Chow Wei, Leong, et al.
Publicado: (2022)

A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva(®) PSP
por: Barello, Serena, et al.
Publicado: (2022)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi, Alessandra, et al.
Publicado: (2013)

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)
por: Centonze, Diego, et al.
Publicado: (2021)

Family Functioning and Multiple Sclerosis: Study Protocol of a Multicentric Italian Project
por: Di Tella, Marialaura, et al.
Publicado: (2021)

Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
por: Durastanti, Valentina, et al.
Publicado: (2011)

Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients
por: Stampanoni Bassi, Mario, et al.
Publicado: (2020)

Correlation analysis between foveal avascular zone and near peripheral retinal hypoperfusion in multiple sclerosis: a wide field optical coherence tomography angiography study
por: Montorio, Daniela, et al.
Publicado: (2022)

Sample Size for Oxidative Stress and Inflammation When Treating Multiple Sclerosis with Interferon-β1a and Coenzyme Q10
por: Moccia, Marcello, et al.
Publicado: (2019)

Impact of HPV vaccination: health gains in the Italian female population
por: Marcellusi, Andrea
Publicado: (2017)

Immunomodulators: interleukins, interferons, and IV immunoglobulin
por: Roelofs, Joris J., et al.
Publicado: (2008)

Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
por: Moccia, Marcello, et al.
Publicado: (2020)

Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data
por: Moccia, Marcello, et al.
Publicado: (2021)

Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study
por: Sbardella, Emilia, et al.
Publicado: (2009)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene
por: Bertoli, Diego, et al.
Publicado: (2015)

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
por: Devonshire, Virginia, et al.
Publicado: (2010)

Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis
por: Iannello, Andrea, et al.
Publicado: (2019)

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study
por: Wysham, Carol H, et al.
Publicado: (2020)

A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects
por: Grimaldi, Luigi Maria Edoardo, et al.
Publicado: (2014)

Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients
por: Reale, Marcella, et al.
Publicado: (2012)

A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment
por: Stampanoni Bassi, Mario, et al.
Publicado: (2020)

Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective
por: Cocito, Dario, et al.
Publicado: (2023)

Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis
por: Moccia, Marcello, et al.
Publicado: (2019)

Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study
por: Devonshire, Virginia A., et al.
Publicado: (2016)

Comparative analysis of the effect of IV administered acid suppressants on gastric pH in dogs
por: Kuhl, Amanda, et al.
Publicado: (2020)

Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4
por: Centonze, Diego, et al.
Publicado: (2023)

Multiple and Variable Binding of Pharmacologically Active Bis(maltolato)oxidovanadium(IV) to Lysozyme
por: Ferraro, Giarita, et al.
Publicado: (2022)

A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.
por: Savage, P., et al.
Publicado: (1996)

Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages
por: Kakizaki, Aya, et al.
Publicado: (2015)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
por: Rolla, Simona, et al.
Publicado: (2020)

Host Genetics and Gut Microbiome: Perspectives for Multiple Sclerosis
por: Maglione, Alessandro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kdraeo4tflq6608sf4a7v9qd72